Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3
Aim. To conduct a direct comparative analysis of single-photon emission computed tomography (SPECT-CT) with [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in patients with HER2-positive breast cancer (BC) with axillary lymph node metastases. Materials and methods. The analysis included 8 patients with HER2...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2025-04-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/5956 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401932947390464 |
|---|---|
| author | О. D. Bragina L. А. Tashireva Е. Yu. Garbukov М. А. Vostrikova А. А. Romanova S. М. Deyev М. Е. Borodina V. I. Chernov |
| author_facet | О. D. Bragina L. А. Tashireva Е. Yu. Garbukov М. А. Vostrikova А. А. Romanova S. М. Deyev М. Е. Borodina V. I. Chernov |
| author_sort | О. D. Bragina |
| collection | DOAJ |
| description | Aim. To conduct a direct comparative analysis of single-photon emission computed tomography (SPECT-CT) with [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in patients with HER2-positive breast cancer (BC) with axillary lymph node metastases. Materials and methods. The analysis included 8 patients with HER2-positive BC with axillary lymph node metastases before the systemic treatment. All patients were injected with [99mTc]Tc-ADAPT6 (500 µg) and [99mTc] Tc-(HE)3-G3 (3,000 µg) with an interval of 3–4 days. The SPECT-CT scans of the chest and upper abdomen were performed after 2 hours for [99mTc]Tc-ADAPT6 and after 4 hours for [99mTc]Tc-(HE)3-G3. The accumulation of radiopharmaceuticals was assessed by measuring the maximum standardized uptake values (SUVmax) in metastatic axillary lymph nodes, projections of the contralateral axillary lymph nodes, liver, latissimus dorsi muscle, and spleen. Additionally, mALN-to-background and mALN-to-reference organs ratios were calculated for each patient. Results. Comparison of the mALN-to-background ratio revealed the advantage of [99mTc]Tc-ADAPT6 (38.93 (16.56–56.02)) over [99mTc]Tc-(HE)3-G3 (19.39 (8.43–34.52)), p = 0.0391. The comparative analysis of the accumulation of the studied radiopharmaceuticals in the reference organs demonstrated higher SUVmax for [99mTc] Tc-(HE)3 -G3 in the liver and spleen (4.44 (2.85–9.08) and 2.47 (1.28–4.41), respectively) than for [99mTc]Tc-ADAPT6 (2.98 (1.96–3.65) and 0.43 (0.14–0.62), respectively), p = 0.01 and p = 0.04. Comparison of the SUVmax ratios in mALN and reference organs showed higher values of mALN / spleen for [99mTc]Tc-ADAPT6 (5.93 (1.04–11.85)) compared to [99mTc]Tc-(HE)3-G3 (1.83 (0.46–4.54)), p = 0.02. Conclusion. According to the results of the performed analysis, the diagnostic advantage of [99mTc]Tc-ADEPT6 for the detection of) HER2/neu expression in metastatic lymph nodes in breast cancer patients was revealed. |
| format | Article |
| id | doaj-art-119b32ca062e40b6b10c67bdd5c94771 |
| institution | Kabale University |
| issn | 1682-0363 1819-3684 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj-art-119b32ca062e40b6b10c67bdd5c947712025-08-20T03:37:41ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842025-04-01241142110.20538/1682-0363-2025-1-14-213130Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3О. D. Bragina0L. А. Tashireva1Е. Yu. Garbukov2М. А. Vostrikova3А. А. Romanova4S. М. Deyev5М. Е. Borodina6V. I. Chernov7Cancer Research Institute, Tomsk National Research Medical Center (Russian Academy of Sciences); National Research Tomsk Polytechnic University (NR TPU)Cancer Research Institute, Tomsk National Research Medical Center (Russian Academy of Sciences)Cancer Research Institute, Tomsk National Research Medical Center (Russian Academy of Sciences)Cancer Research Institute, Tomsk National Research Medical Center (Russian Academy of Sciences)Cancer Research Institute, Tomsk National Research Medical Center (Russian Academy of Sciences)National Research Tomsk Polytechnic University (NR TPU); Shemyakin – Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences; National Research Center «Kurchatov Institute»P. Hertsen Moscow Oncology Research InstituteCancer Research Institute, Tomsk National Research Medical Center (Russian Academy of Sciences); National Research Tomsk Polytechnic University (NR TPU); National Research Center «Kurchatov Institute»Aim. To conduct a direct comparative analysis of single-photon emission computed tomography (SPECT-CT) with [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 in patients with HER2-positive breast cancer (BC) with axillary lymph node metastases. Materials and methods. The analysis included 8 patients with HER2-positive BC with axillary lymph node metastases before the systemic treatment. All patients were injected with [99mTc]Tc-ADAPT6 (500 µg) and [99mTc] Tc-(HE)3-G3 (3,000 µg) with an interval of 3–4 days. The SPECT-CT scans of the chest and upper abdomen were performed after 2 hours for [99mTc]Tc-ADAPT6 and after 4 hours for [99mTc]Tc-(HE)3-G3. The accumulation of radiopharmaceuticals was assessed by measuring the maximum standardized uptake values (SUVmax) in metastatic axillary lymph nodes, projections of the contralateral axillary lymph nodes, liver, latissimus dorsi muscle, and spleen. Additionally, mALN-to-background and mALN-to-reference organs ratios were calculated for each patient. Results. Comparison of the mALN-to-background ratio revealed the advantage of [99mTc]Tc-ADAPT6 (38.93 (16.56–56.02)) over [99mTc]Tc-(HE)3-G3 (19.39 (8.43–34.52)), p = 0.0391. The comparative analysis of the accumulation of the studied radiopharmaceuticals in the reference organs demonstrated higher SUVmax for [99mTc] Tc-(HE)3 -G3 in the liver and spleen (4.44 (2.85–9.08) and 2.47 (1.28–4.41), respectively) than for [99mTc]Tc-ADAPT6 (2.98 (1.96–3.65) and 0.43 (0.14–0.62), respectively), p = 0.01 and p = 0.04. Comparison of the SUVmax ratios in mALN and reference organs showed higher values of mALN / spleen for [99mTc]Tc-ADAPT6 (5.93 (1.04–11.85)) compared to [99mTc]Tc-(HE)3-G3 (1.83 (0.46–4.54)), p = 0.02. Conclusion. According to the results of the performed analysis, the diagnostic advantage of [99mTc]Tc-ADEPT6 for the detection of) HER2/neu expression in metastatic lymph nodes in breast cancer patients was revealed.https://bulletin.ssmu.ru/jour/article/view/5956breast canceradapt6darping3radionuclide diagnosis |
| spellingShingle | О. D. Bragina L. А. Tashireva Е. Yu. Garbukov М. А. Vostrikova А. А. Romanova S. М. Deyev М. Е. Borodina V. I. Chernov Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 Бюллетень сибирской медицины breast cancer adapt6 darping3 radionuclide diagnosis |
| title | Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 |
| title_full | Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 |
| title_fullStr | Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 |
| title_full_unstemmed | Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 |
| title_short | Radionuclide imaging of HER2/neu expression in metastatic axillary lymph nodes in breast cancer patients: comparing the efficacy of [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 |
| title_sort | radionuclide imaging of her2 neu expression in metastatic axillary lymph nodes in breast cancer patients comparing the efficacy of sup 99m sup tc tc adapt6 and sup 99m sup tc tc he sub 3 sub g3 |
| topic | breast cancer adapt6 darping3 radionuclide diagnosis |
| url | https://bulletin.ssmu.ru/jour/article/view/5956 |
| work_keys_str_mv | AT odbragina radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT latashireva radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT eyugarbukov radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT mavostrikova radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT aaromanova radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT smdeyev radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT meborodina radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 AT vichernov radionuclideimagingofher2neuexpressioninmetastaticaxillarylymphnodesinbreastcancerpatientscomparingtheefficacyofsup99msuptctcadapt6andsup99msuptctchesub3subg3 |